Related references
Note: Only part of the references are listed.Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
Baoshan Zhang et al.
MABS (2023)
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Piotr Celichowski et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2023)
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
Anthony Mills et al.
AIDS (2022)
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals
Brian Moldt et al.
AIDS (2022)
Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older
Marie Joelle Jabagi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
Sharana Mahomed et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
Amarendra Pegu et al.
CELL REPORTS (2022)
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection
Mary S. Pampusch et al.
PLOS PATHOGENS (2022)
Implications of the accumulation of CXCR5+ NK cells in lymph nodes of HIV-1 infected patients
An-Liang Guo et al.
EBIOMEDICINE (2022)
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial
Henning Gruell et al.
LANCET MICROBE (2022)
The association between COVID-19 vaccination and Bell's palsy Comment
Nicola Cirillo et al.
LANCET INFECTIOUS DISEASES (2022)
Combination anti-HIV antibodies provide sustained virological suppression
Michael C. Sneller et al.
NATURE (2022)
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
Joseph P. Casazza et al.
NATURE MEDICINE (2022)
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg et al.
NATURE MEDICINE (2022)
Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-site
Tongqing Zhou et al.
STRUCTURE (2022)
Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine
Min Guan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)
Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection
Sheikh Abdul Rahman et al.
JCI INSIGHT (2022)
Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore
Tian Ming Tu et al.
JAMA NETWORK OPEN (2022)
Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells
Brianna C. Davey et al.
FRONTIERS IN IMMUNOLOGY (2022)
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K Gupta et al.
Lancet HIV (2022)
In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice
Alessio D. Nahmad et al.
NATURE BIOTECHNOLOGY (2022)
Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4
Hugh C. Welles et al.
PLOS PATHOGENS (2022)
Myocarditis or Pericarditis Following mRNA COVID-19 Vaccination
Eric S. Weintraub et al.
JAMA NETWORK OPEN (2022)
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Jesper D. Gunst et al.
NATURE MEDICINE (2022)
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
Tumelo Moshoette et al.
VIROLOGY JOURNAL (2022)
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity
Miriam Rosas-Umbert et al.
NATURE COMMUNICATIONS (2022)
Acute cardiac side effects after COVID-19 mRNA vaccination: a case series
Noemi F. Freise et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2022)
Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia
Yoshiaki Nishimura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies
Sarah J. Nagle et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
Kathryn E. Stephenson et al.
NATURE MEDICINE (2021)
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
Allison August et al.
NATURE MEDICINE (2021)
Cytotoxic CD8+T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged In Vitro Peptide Stimulation
Philipp Adams et al.
FRONTIERS IN IMMUNOLOGY (2021)
Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121
Wen Shi Lee et al.
FRONTIERS IN IMMUNOLOGY (2021)
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
L. Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children
Stefania Dispinseri et al.
VACCINES (2021)
A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription
Chen-liang Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Functional impairment of HIV-specific CD8+T cells precedes aborted spontaneous control of viremia
David R. Collins et al.
IMMUNITY (2021)
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
Amarendra Pegu et al.
SCIENCE (2021)
Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression
Mengyue Niu et al.
CELL REPORTS (2021)
HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo
Zhengtao Jiang et al.
FRONTIERS IN MICROBIOLOGY (2021)
Characterizing the Relationship Between Neutralization Sensitivity and env Gene Diversity During ART Suppression
Andrew Wilson et al.
FRONTIERS IN IMMUNOLOGY (2021)
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART(R) Molecules
Marina Tuyishime et al.
FRONTIERS IN IMMUNOLOGY (2021)
Broadly neutralizing antibody derived CAR T cells reduce viral reservoir in individuals infected with HIV-1
Bingfeng Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies
Ying Wang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants
Coleen K. Cunningham et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
Philipp Schommers et al.
CELL (2020)
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Julia Niessl et al.
NATURE MEDICINE (2020)
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription
Pieter Pannus et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2020)
Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
Kathryn E. Stephenson et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma
Jun-Xia Cao et al.
CYTOTHERAPY (2020)
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay
Sulggi A. Lee et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
Evan M. Cale et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
HIV-Resistant and HIV-Specific CAR-Modified CD4+ T Cells Mitigate HIV Disease Progression and Confer CD4+ T Cell Help In Vivo
Colby R. Maldini et al.
MOLECULAR THERAPY (2020)
No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection
Basma Abdi et al.
AIDS (2020)
Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels
Changze Han et al.
MBIO (2020)
A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite
Sonu Kumar et al.
SCIENCE ADVANCES (2020)
Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion
Alessio D. Nahmad et al.
NATURE COMMUNICATIONS (2020)
Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells
Deli Huang et al.
NATURE COMMUNICATIONS (2020)
Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection
Ananya Saha et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Engineered Antigen-Specific T Cells Secreting Broadly Neutralizing Antibodies: Combining Innate and Adaptive Immune Response against HIV
Allison B. Powell et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma
Vanessa E. Kennedy et al.
BLOOD (2020)
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
Sharana Mahomed et al.
BMJ OPEN (2020)
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
Sharana Mahomed et al.
BMJ OPEN (2020)
Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression
Jose M. Martinez-Navio et al.
IMMUNITY (2019)
Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control
Christopher W. Pohlmeyer et al.
JOURNAL OF VIROLOGY (2019)
Reduction of HIV-1 Reservoir Size and Diversity After 1 Year of cART Among Brazilian Individuals Starting Treatment During Early Stages of Acute Infection
Thaysse Ferreira Leite et al.
FRONTIERS IN MICROBIOLOGY (2019)
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
Frances H. Priddy et al.
LANCET HIV (2019)
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Till Schoofs et al.
IMMUNITY (2019)
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells
Harald Hartweger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection
Zaza M. Ndhlovu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
Giulia Calenda et al.
PLOS PATHOGENS (2019)
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
Trevor A. Crowell et al.
LANCET HIV (2019)
Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
Brian C. Mackness et al.
MABS (2019)
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
Prasanta K. Dash et al.
NATURE COMMUNICATIONS (2019)
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Yehuda Z. Cohen et al.
PLOS ONE (2019)
Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model
Kim Anthony-Gonda et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
Dora Pinto et al.
CELL HOST & MICROBE (2019)
Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function
Hillary G. Caruso et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
Martin R. Gaudinski et al.
LANCET HIV (2019)
HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Christine A. Bricault et al.
CELL HOST & MICROBE (2019)
Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis
Joris Hemelaar et al.
LANCET INFECTIOUS DISEASES (2019)
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
Matthew R. Gardner et al.
MOLECULAR THERAPY (2019)
Ibalizumab for the treatment of multidrug-resistant HIV-1 infection
S. A. Rizza et al.
DRUGS OF TODAY (2019)
Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
Nika M. Strokappe et al.
ANTIBODIES (2019)
Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses
Mohammad Mohseni Sajadi et al.
CELL (2018)
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
Kush Dhody et al.
HIV CLINICAL TRIALS (2018)
A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope
Tongqing Zhou et al.
IMMUNITY (2018)
Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice
Xilin Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Broad neutralization response in a subset of HIV-1 subtype C-infected viraemic non-progressors from southern India
Paneerselvam Nandagopal et al.
JOURNAL OF GENERAL VIROLOGY (2018)
Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs
Johannes Brozy et al.
JOURNAL OF VIROLOGY (2018)
A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection
Rajeev Gautam et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
Martin R. Gaudinski et al.
PLOS MEDICINE (2018)
Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies
Hongye Wang et al.
ARCHIVES OF VIROLOGY (2018)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
Yotam Bar-On et al.
NATURE MEDICINE (2018)
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Brinda Emu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evolution of HIV-1 within untreated individuals and at the population scale in Uganda
Jayna Raghwani et al.
PLOS PATHOGENS (2018)
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Erica N. Borducchi et al.
NATURE (2018)
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability
Marit J. van Gils et al.
NATURE MICROBIOLOGY (2017)
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage
Elise Landais et al.
IMMUNITY (2017)
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop
Evan M. Cale et al.
IMMUNITY (2017)
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Malika Hale et al.
MOLECULAR THERAPY (2017)
Early antibody therapy can induce long-lasting immunity to SHIV
Yoshiaki Nishimura et al.
NATURE (2017)
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey et al.
NATURE MEDICINE (2017)
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Ling Xu et al.
SCIENCE (2017)
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
Natalia T. Freund et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
S. Munir Alam et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies
Mattia Bonsignori et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
Kathrin Koch et al.
SCIENTIFIC REPORTS (2017)
In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a Block-and-Lock'' Strategy for HIV-1 Treatment
Cari F. Kessing et al.
CELL REPORTS (2017)
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
Kenneth H. Mayer et al.
PLOS MEDICINE (2017)
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
LaTonya D. Williams et al.
SCIENCE IMMUNOLOGY (2017)
Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy
William J. Hey-Nguyen et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2017)
Evaluating and Reporting the Immunogenicity Impacts for Biological Products-a Clinical Pharmacology Perspective
Yow-Ming C. Wang et al.
AAPS JOURNAL (2016)
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency
Nicole A. Doria-Rose et al.
JOURNAL OF VIROLOGY (2016)
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Yaoxing Huang et al.
CELL (2016)
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Mattia Bonsignori et al.
CELL (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal et al.
CELL (2016)
A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans
Devin Sok et al.
IMMUNITY (2016)
Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch
Daniel T. MacLeod et al.
IMMUNITY (2016)
Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
Jinghe Huang et al.
IMMUNITY (2016)
Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding
Nancy S. Longo et al.
JOURNAL OF VIROLOGY (2016)
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies
Ayub Ali et al.
JOURNAL OF VIROLOGY (2016)
Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys
Jose M. Martinez-Navio et al.
MOLECULAR THERAPY (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid et al.
NATURE (2016)
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
Ran He et al.
NATURE (2016)
CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles
Yew Ann Leong et al.
NATURE IMMUNOLOGY (2016)
Determinants of HIV-1 broadly neutralizing antibody induction
Peter Rusert et al.
NATURE MEDICINE (2016)
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site
Harry B. Gristick et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
K. J. Bar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors
Muntasir Alam et al.
RETROVIROLOGY (2016)
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody
Rui Kong et al.
SCIENCE (2016)
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site
Harry B. Gristick et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort
Elise Landais et al.
PLOS PATHOGENS (2016)
Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance
Sam Song et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
Tongqing Zhou et al.
CELL (2015)
Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection
Xueling Wu et al.
CELL (2015)
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
J. E. Ledgerwood et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
Tessa Gargett et al.
CYTOTHERAPY (2015)
Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization
M. Asokan et al.
JOURNAL OF VIROLOGY (2015)
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
Li Liu et al.
JOURNAL OF VIROLOGY (2015)
HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells
Anjie Zhen et al.
MOLECULAR THERAPY (2015)
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Marina Caskey et al.
NATURE (2015)
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Kai Deng et al.
NATURE (2015)
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
Jinal N. Bhiman et al.
NATURE MEDICINE (2015)
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
Maarten Van Roy et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Activation and lysis of human CD4 cells latently infected with HIV-1
Amarendra Pegu et al.
NATURE COMMUNICATIONS (2015)
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
Derek D. Sloan et al.
PLOS PATHOGENS (2015)
A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo
Natalia T. Freund et al.
PLOS PATHOGENS (2015)
Polyreactivity and Autoreactivity among HIV-1 Antibodies
Mengfei Liu et al.
JOURNAL OF VIROLOGY (2015)
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Peter Hraber et al.
AIDS (2014)
Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies
Thomas B. Kepler et al.
CELL HOST & MICROBE (2014)
Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers
Emilia Falkowska et al.
IMMUNITY (2014)
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Allan deCamp et al.
JOURNAL OF VIROLOGY (2014)
Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies
Peter Hraber et al.
JOURNAL OF VIROLOGY (2014)
Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo
Rebecca S. Rudicell et al.
JOURNAL OF VIROLOGY (2014)
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface
Jinghe Huang et al.
NATURE (2014)
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Sung-Youl Ko et al.
NATURE (2014)
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nicole A. Doria-Rose et al.
NATURE (2014)
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
Alejandro B. Balazs et al.
NATURE MEDICINE (2014)
Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection
Siddappa N. Byrareddy et al.
NATURE MEDICINE (2014)
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues
Courtney V. Fletcher et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex
Devin Sok et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy
Mary F. Kearney et al.
PLOS PATHOGENS (2014)
Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization
Florian Klein et al.
CELL (2013)
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production
Matthieu Perreau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies
Guang Yang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion
Frank Maldarelli et al.
JOURNAL OF VIROLOGY (2013)
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Masashi Shingai et al.
NATURE (2013)
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
Dan H. Barouch et al.
NATURE (2013)
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Hua-Xin Liao et al.
NATURE (2013)
Phenotypic properties of transmitted founder HIV-1
Nicholas F. Parrish et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization
Ivelin S. Georgiev et al.
SCIENCE (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor
Jenna Rychert et al.
VIROLOGY JOURNAL (2013)
Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes
Constantinos Kurt Wibmer et al.
PLOS PATHOGENS (2013)
Evidence for a Continuous Drift of the HIV-1 Species towards Higher Resistance to Neutralizing Antibodies over the Course of the Epidemic
Melanie Bouvin-Pley et al.
PLOS PATHOGENS (2013)
Correction: The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies
Devin Sok et al.
PLoS Pathogens (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
Pauline A. van Schouwenburg et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization
Laura E. McCoy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins
Yuxing Li et al.
JOURNAL OF VIROLOGY (2012)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang et al.
NATURE (2012)
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
Penny L. Moore et al.
NATURE MEDICINE (2012)
Llama Antibody Fragments Recognizing Various Epitopes of the CD4bs Neutralize a Broad Range of HIV-1 Subtypes A, B and C
Nika Strokappe et al.
PLOS ONE (2012)
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
Hugo Mouquet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies
Zhongyu Zhu et al.
JOURNAL OF VIROLOGY (2011)
Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors
Mattia Bonsignori et al.
JOURNAL OF VIROLOGY (2011)
Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M. Walker et al.
NATURE (2011)
Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting
Lynn Morris et al.
PLOS ONE (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
Xueling Wu et al.
SCIENCE (2011)
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
Johannes F. Scheid et al.
SCIENCE (2011)
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
A. Vultaggio et al.
ALLERGY (2010)
Differential tumor-targeting abilities of three single-domain antibody formats
Andrea Bell et al.
CANCER LETTERS (2010)
Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange
Michael Huber et al.
JOURNAL OF VIROLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu et al.
SCIENCE (2010)
Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control
Adam R. Hersperger et al.
PLOS PATHOGENS (2010)
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Laura M. Walker et al.
SCIENCE (2009)
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
Thomas Tiller et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
Saurabh Mehandru et al.
JOURNAL OF VIROLOGY (2007)
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
Amapola Manrique et al.
JOURNAL OF VIROLOGY (2007)
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004
Joris Hemelaar et al.
AIDS (2006)
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
BF Haynes et al.
SCIENCE (2005)
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
A Trkola et al.
NATURE MEDICINE (2005)
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5
MB Zwick et al.
JOURNAL OF VIROLOGY (2004)
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
MB Zwick et al.
JOURNAL OF VIROLOGY (2003)
Antibody neutralization and escape by HIV-1
XP Wei et al.
NATURE (2003)
Human immunodeficiency virus type 1 recombination: Rate, fidelity, and putative hot spots
JL Zhuang et al.
JOURNAL OF VIROLOGY (2002)
Antiviral activity of the neutralizing antibodies 2F5 and 2612 in asymptomatic HIV-1-infected humans:: a phase I evaluation
G Stiegler et al.
AIDS (2002)
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy
SG Deeks et al.
MOLECULAR THERAPY (2002)
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1
C Armbruster et al.
AIDS (2002)
Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects
RT Mitsuyasu et al.
BLOOD (2000)
Share Paper
